Showing results (551-560 of 635) with videos related to

Sort By:
Pageof 64
Nature Medicine|September 1, 2024
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomesMuthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett, et al.
JACC. Heart Failure|March 6, 2025
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVERRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Orthopaedic Journal of Sports Medicine|January 2, 2026
3D Patellar instability Anatomical Severity Score (3D-PASS): A Novel Machine Learning Score Using 3D Bone Position From MRI to Predict Outcomes of Patellar Instability Treatment (Using a Subset of Data in the JUPITER Cohort)Marissa L Sinopoli, Anthony A Gatti, Christian E Wright, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
Circulation. Heart Failure|September 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HFMisato Chimura, Mark C Petrie, Morten Schou, et al.
Pageof 64